Eli Lilly and Company (LLY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2025 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will be conducting a question and answer session and instructions will be given at that time. Should you request assistance during the call, please press star, then zero, and an operator will assist you offline. I would now like to turn the conference over to your host, Mike Zappar, Senior Vice President of Investor Relations. Please go ahead. Well, good morning. Thank you for joining us for Eli Lilly and Company's Q4 2025 Earnings Call. I'm Mike Sapar, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chair and CEO, Lucas Montarse, Chief Financial Officer, Dr. Dan Skowronski, Chief Scientific and Product Officer, Adrian Brown, President of Lilly Immunology, Dr. Carol Ho, President of Lilly Neuroscience, Olivia Ufa, President of Lilly USA and Global Customer Capabilities, Jake Van Narden, President of Biology and Head of Business Development, Patrick Janssen, President of Lilly International, and Ken Custer, President of Lilly Cardiometabolic Health. We're also joined by Mark Keeman, Susan Hedgeland, and Wes Tall of the Investor Relations Team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on slide four. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K, Subsequent Filings with the SEC. The information we provide about our products and pipeline is for the benefit of the investment community. It does n...